Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001883850-23-000090 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-12 | 2023-12-08+ | REGN | STAHL NEIL | EVP Research, Development | F - Tax | $843.93 | -1,534 | 52.0K | -3% | -$1.29M |
| D | 2023-12-12 | 2023-12-08 | REGN | STAHL NEIL | EVP Research, Development | A - Grant | $0.00 | +853 | 52.7K | +2% | $0 |
| D | 2023-12-12 | 2023-12-08 | REGN | STAHL NEIL | EVP Research, Development | A - Grant | $0.00 | +3,059 | 3,059 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-08 | F | D | 809 | $843.79 | 51,891 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-08 | A | A | 853 | $0.00 | 52,744 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-11 | F | D | 725 | $844.09 | 52,019 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-08 | A | A | 3,059 | $0.00 | 3,059 | D | $843.79 · — to 2033-12-08 | 3,059 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |